Back to Search Start Over

Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial

Authors :
Sifat, Munjireen
Hébert, Emily
Ahluwalia, Jasjit
Businelle, Michael
Waring, Joseph
Frank-Pearce, Summer
Bryer, Chase
Benson, Lizbeth
Madison, Stefani
Planas, Lourdes
Baranskaya, Irina
Kendzor, Darla
Sifat, Munjireen
Hébert, Emily
Ahluwalia, Jasjit
Businelle, Michael
Waring, Joseph
Frank-Pearce, Summer
Bryer, Chase
Benson, Lizbeth
Madison, Stefani
Planas, Lourdes
Baranskaya, Irina
Kendzor, Darla
Source :
Department of Medical Oncology Faculty Papers
Publication Year :
2023

Abstract

BACKGROUND: Varenicline and oral nicotine replacement therapy (NRT) have each been shown to increase the likelihood of smoking cessation, but their combination has not been studied. In addition, smoking cessation medication adherence is often poor, thus, challenging the ability to evaluate medication efficacy. OBJECTIVE: This study examined the effects of combined varenicline and oral NRT and smartphone medication reminders on pharmacotherapy adherence and smoking abstinence among adults enrolled in smoking cessation treatment. METHODS: A 2×2 factorial design was used. Participants (N=34) were randomized to (1) varenicline + oral NRT (VAR+NRT) or varenicline alone (VAR) and (2) smartphone medication reminder messages (REM) or no reminder messages (NREM) over 13 weeks. Participants assigned to VAR+REM received varenicline reminder prompts, and those assigned to VAR+NRT+REM also received reminders to use oral NRT. The other 2 groups (VAR+NREM and VAR+NRT+NREM) did not receive medication reminders. Participants were not blinded to intervention groups. All participants received tobacco cessation counseling. Smartphone assessments of smoking as well as varenicline and NRT use (if applicable) were prompted daily through the first 12 weeks after a scheduled quit date. Descriptive statistics were generated to characterize the relations between medication and reminder group assignments with daily smoking, daily varenicline adherence, and daily quantity of oral NRT used. Participants completed follow-up assessments for 26 weeks after the quit date. RESULTS: Participants were predominantly White (71%), and half were female (50%). On average, participants were 54.2 (SD 9.4) years of age, they smoked an average of 19.0 (SD 9.0) cigarettes per day and had smoked for 34.6 (SD 12.7) years. Descriptively, participants assigned to VAR+NRT reported more days of smoking abstinence compared to VAR (29.3 vs 26.3 days). Participants assigned to REM reported more days of smoking abstinence

Details

Database :
OAIster
Journal :
Department of Medical Oncology Faculty Papers
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1422118899
Document Type :
Electronic Resource